Introduction:

This guide summarizes how Ipamorelin has been dosed in published research and common experimental designs.¹²
Ipamorelin is a selective growth hormone secretagogue that stimulates pulsatile GH release via the ghrelin receptor (GHSR-1a).¹²

Disclaimer: The information below is for educational and research purposes only. Ipamorelin is not approved for human use. No medical advice is given.

Typical Research Dosage Parameters

Study Context	Subject Type	Typical Daily Dose Range	Frequency	Duration	Notes
GH release studies¹²	Human	200–600 mcg	1–3x daily	Single or up to 14 days	GH peaks ~30 min post-dose
Muscle injury models⁵	Rodent	200–400 mcg/kg	1x daily	7–14 days	Supports tissue repair biomarkers
Body composition models³	Rodent	100–300 mcg/kg	1–2x daily	4–8 weeks	Lean mass ↑, fat ↓
Combination with CJC-1295⁶	Human	Ipamorelin 200–300 mcg + CJC-1295 1–2 mg weekly	Ipamorelin 1–2x daily	1–2 weeks	Synergistic GH pulse

TB-500 Dosing Protocols: Animal & Cell Studies

Study Type	Dose Range	Frequency	Duration	Route	Notes
Rodent¹²	2–10 mg/kg	Daily	7–14 days	SC, IM, IV	Wound, heart, tendon healing
Rabbit / Large Animal³	0.5–5 mg/kg	Daily or 2×/wk	2–6 weeks	SC, IM	Tendon/ligament models
In vitro⁴	10–100 nM	N/A	Up to 7 days	Cell culture	Cell migration and signaling assays

1. Human Study Dosage Ranges¹²

In human GH release studies, Ipamorelin has typically been dosed between 200–600 mcg per injection, once to three times daily. GH peaks occur approximately 30 minutes post-injection, with levels returning to baseline within 2 hours.
Why this matters: This short half-life allows for controlled, pulsatile GH release.

2. Animal Study Dosage Ranges³⁵

In rodent models, dosing is often expressed per kg of body weight, commonly 100–400 mcg/kg/day. Studies have examined endpoints like lean mass change, tissue regeneration, and metabolic biomarkers.
Why this matters: These models help define possible dose–response relationships for tissue repair and metabolism.

3. Frequency Considerations²

Because Ipamorelin acts rapidly and clears quickly, multiple daily injections can be used in some protocols to simulate physiologic GH pulsatility.
Why this matters: In GH research, pulsatility is linked to anabolic signaling efficiency.

4. Stacking Protocols⁶

Ipamorelin is sometimes co-administered with GHRH analogs such as CJC-1295 or Modified GRF(1-29). The two peptides act via complementary pathways to amplify GH secretion.
Why this matters: Combination protocols can produce higher and longer GH pulses than Ipamorelin alone.

5. Duration of Research Protocols

Human studies often run 1–2 weeks for acute endocrine response testing. Rodent models may last several weeks for muscle, bone, or metabolic endpoints.
Why this matters: Duration impacts observed outcomes—short-term for biomarker changes, long-term for structural or performance effects.

Limitations

• Dosing data is mostly from short-term studies
  
• Few standardized protocols across labs
  
• Rodent doses cannot be directly converted to human equivalent doses without appropriate scaling

Conclusion

Ipamorelin dosing in research varies by species, study design, and endpoint, but typically falls between 200–600 mcg 1–3x daily in human studies and 100–400 mcg/kg/day in animal models. Its short-acting, pulse-like GH stimulation and synergy with GHRH analogs make it a versatile tool for endocrine and tissue repair research.

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, a novel pentapeptide growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. https://pubmed.ncbi.nlm.nih.gov/9849815/
   
2. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999;16(9):1473–1479. https://pubmed.ncbi.nlm.nih.gov/10496658/
   
3. Walker RF, et al. Endocrine and metabolic effects of ipamorelin in laboratory animals. Growth Horm IGF Res. 1999;9(4):352–360. https://pubmed.ncbi.nlm.nih.gov/10611799/
   
4. Ghigo E, et al. Endocrine and non-endocrine activities of growth hormone secretagogues. J Endocrinol Invest. 1999;22(5 Suppl):5–10. https://pubmed.ncbi.nlm.nih.gov/10592438/
   
5. Liu Z, et al. Ghrelin receptor agonist improves muscle regeneration in aged mice. Aging Cell. 2017;16(5):1083–1093. https://pubmed.ncbi.nlm.nih.gov/28703462/
   
6. Casanueva FF, et al. Synergistic action of GHRH and GHS on GH release. Trends Endocrinol Metab. 1999;10(1):30–38. https://www.sciencedirect.com/science/article/abs/pii/S1043276098001167